<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925794</url>
  </required_header>
  <id_info>
    <org_study_id>COBRA 2012-01</org_study_id>
    <nct_id>NCT01925794</nct_id>
  </id_info>
  <brief_title>The PzF Shield Trial</brief_title>
  <official_title>COBRA PZF™ Coronary Stent System in Native Coronary Arteries for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term Dual Anti-Platelet Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CeloNova BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CeloNova BioSciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, non-randomized, single arm clinical trial that will be
      conducted at up to 40 sites in the United States and Outside United States (OUS). This study
      will enroll patients with symptomatic ischemic heart disease due to a single de novo lesion
      contained within a native coronary artery with reference vessel diameter between 2.5 mm and
      4.0 mm and lesion length ≤ 24 mm that is amenable to percutaneous coronary intervention (PCI)
      and stent deployment. All patients will be followed at 30 days, 6 months, 9 months, 1 year
      and annually for 5 years post index stenting procedure.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PzF Shield</measure>
    <time_frame>270 days</time_frame>
    <description>The primary endpoint will be the incidence of Target Vessel Failure (TVF) within 270 days of treatment with the COBRA PzFTM Coronary Stent System.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PzF Shield: Secondary Endpoint 1</measure>
    <time_frame>30, 180, 270, 360, 720, 1080, 1440 and 1800 days</time_frame>
    <description>1. All Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pzf Shield: Secondary Endpoint 2</measure>
    <time_frame>30,180,270.360,720,1080,1440 and 1800 days</time_frame>
    <description>2. Cardiac Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield-Secondary Endpoint 3</measure>
    <time_frame>30,180,270,360,720,1080,1440, and 1800 days</time_frame>
    <description>3. Major Adverse Events (MACE), defined as cardiac death, Myocardial Infarction (MI), emergent bypass surgery, or clinically driven Target Lesion REvascularization (TLR) by percutaneous or surgical methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield- Secondary Endpoint 4</measure>
    <time_frame>30,180,270,360,720,1080,1440, and 1800 days</time_frame>
    <description>MI clinically driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield-Secondary Endpoint 5</measure>
    <time_frame>30,180,270,360 days</time_frame>
    <description>Stroke (Ischemic and hemorrhagic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield- Secondary Endpoint 6</measure>
    <time_frame>30,180,270,360 days</time_frame>
    <description>Clinically driven TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield- Secondary Endpoint 7</measure>
    <time_frame>30,180,270,360 days</time_frame>
    <description>Composite Endpoint of Cardiac Death and MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield- Secondary Endpoint 8</measure>
    <time_frame>30,180,360 days</time_frame>
    <description>Target Vessel Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield- Secondary Endpoint 9</measure>
    <time_frame>Hospital Discharge</time_frame>
    <description>Bleeding or Vascular Complications at hospital Discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield-Secondary Endpoint 10</measure>
    <time_frame>30 days</time_frame>
    <description>Early Stent Thrombosis (ARC) defined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield- Secondary Endpoint 11</measure>
    <time_frame>180, 270 and 360 days</time_frame>
    <description>Late Stent Thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield-Secondary Endpoint 12</measure>
    <time_frame>270 days</time_frame>
    <description>Angiographic Endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PzF Shield- Secondary Endpoint 13</measure>
    <time_frame>270 days</time_frame>
    <description>Optical Coherence Tomography Endpoints</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">296</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>COBRA PzF Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>COBRA PzF</intervention_name>
    <arm_group_label>COBRA PzF Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. Patient &gt;/= to 18 years old.

          2. Eligible for percutaneous coronary intervention (PCI).

          3. Patient understands the nature of the procedure and provides written informed consent
             prior to the catheterization procedure.

          4. Patient is willing to comply with specified follow-up evaluation and can be contacted
             by telephone.

          5. Acceptable candidate for coronary artery bypass graft (CABG) surgery.

          6. Stable angina pectoris (Canadian Cardiovascular Society (CCS) 1, 2, 3 or 4) or
             unstable angina pectoris (Braunwald Class 1-3, B-C) or a positive functional ischemia
             study (e.g., ETT, SPECT, Stress echocardiography or Cardiac CT).

          7. Male or non-pregnant female patient (Note: females of child bearing potential must
             have a negative pregnancy test prior to enrollment in the study).

        Angiographic Inclusion Criteria

          1. Patient indicated for elective stenting of a single stenotic lesion in a native
             coronary artery.

          2. Reference vessel &gt;/= 2.5 mm and &lt;/= 4.0 mm in diameter by visual estimate.

          3. Target lesion &lt;/= 24 mm in length by visual estimate (the intention should be to cover
             the whole lesion with one stent of adequate length).

          4. Protected left main lesion with &gt;50% stenosis.

          5. Target lesion stenosis &gt;/= 70% and &lt; 100% by visual estimate.

          6. Target lesion stenosis &lt;70% who meet physiological criteria for revascularization
             (i.e. positive FFR).

        General Exclusion Criteria:

          1. Currently enrolled in another investigational device or drug trial that has not
             completed the primary endpoint or that clinically interferes with the current study
             endpoints.

          2. Previously enrolled in another stent trial within the prior 2 years.

          3. ANY planned elective surgery or percutaneous intervention within the subsequent 3
             months.

          4. A previous coronary interventional procedure of any kind within 30 days prior to the
             procedure.

          5. The patient requires staged procedure of either the target or any non-target vessel
             within 9 months post-procedure.

          6. The target lesion requires treatment with a device other than PTCA prior to stent
             placement (such as, but not limited to, directional coronary atherectomy, excimer
             laser, rotational atherectomy, etc.).

          7. Previous drug eluting stent (DES) deployment anywhere in the target vessel.

          8. Any previous stent placement within 15 mm (proximal or distal) of the target lesion.

          9. Co-morbid condition(s) that could limit the patient's ability to participate in the
             trial or to comply with follow-up requirements, or impact the scientific integrity of
             the trial.

         10. Concurrent medical condition with a life expectancy of less than 12 months.

         11. Documented left ventricular ejection fraction (LVEF) &lt; 30% within 12 months prior to
             enrollment.

         12. Patients with diagnosis of MI within 72 hours (i.e. CK-MB must be returned to normal
             prior to enrollment) or suspected acute MI at time of enrollment

         13. Previous brachytherapy in the target vessel.

         14. History of cerebrovascular accident or transient ischemic attack in the last 6 months.

         15. Leukopenia (leukocytes &lt; 3.5 x 10(9) / liter).

         16. Neutropenia (Absolute Neutrophil Count &lt; 1000/mm3) &lt;/= 3 days prior to enrollment.

         17. Thrombocytopenia (platelets &lt; 100,000/mm3) pre-procedure.

         18. Active peptic ulcer or active GI bleeding.

         19. History of bleeding diathesis or coagulopathy or inability to accept blood
             transfusions.

         20. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin,
             clopidogrel or ticlopidine, cobalt, nickel, L-605 Cobalt chromium alloy or sensitivity
             to contrast media, which cannot be adequately pre-medicated.

         21. Serum creatinine level &gt; 2.0 mg/dl within 7 days prior to index procedure.

         22. Patients unable to tolerate dual anti-platelets therapy (DAPT) for one month post
             procedure.

        Angiographic Exclusion Criteria

          1. Unprotected left main coronary artery disease (obstruction greater than 50% in the
             left main coronary artery that is not protected by at least one non-obstructed bypass
             graft to the LAD or Circumflex artery or a branch thereof).

          2. Target vessel with any lesions with greater than 50% diameter stenosis outside of a
             range of 5 mm proximal and distal to the target lesion based on visual estimate or
             on-line QCA.

          3. Target lesion (or vessel) exhibiting an intraluminal thrombus (occupying &gt; 50% of the
             true lumen diameter) at any time.

          4. Lesion location that is aorto-ostial or within 5 mm of the origin of the left anterior
             descending (LAD) or left circumflex (LCX).

          5. Target lesion with side branches &gt; 2.0mm in diameter.

          6. Target vessel is excessively tortuous (two bends &gt; 90˚ to reach the target lesion).

          7. Target lesion is severely calcified.

          8. TIMI flow 0 or 1

          9. Target lesion is in a bypass graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Cutlip, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Executive Director, Clinical Investigation, Harvard Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sigmund Sliber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine at The University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bakersfield Memorial Hospital</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Heart Hospital</name>
      <address>
        <city>Lacombe</city>
        <state>Louisiana</state>
        <zip>70445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart &amp; Lung Center</name>
      <address>
        <city>Brown Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation for Cardiovascular Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Oregon Cardiology</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York General Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plaza Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Endovascular &amp; Heart Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cardiovascular Consultants</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cardiovascular Specialists</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspirus Heart &amp; Vascular Institute</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Axium</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13097</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Diaconat</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St. Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankt Kathatinen Hospital</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologische Praxis und Praxisklinik</name>
      <address>
        <city>Munchen</city>
        <zip>81379</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>2166</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <disposition_first_submitted>January 30, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 31, 2017</disposition_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stent, Coronary Arteries for Early healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 8, 2017</submitted>
    <returned>April 19, 2017</returned>
    <submitted>May 19, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 31, 2017</submitted>
    <returned>December 8, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

